LEXICON PHARMACEUTICALS, INC. Goodwill
LEXICON PHARMACEUTICALS, INC. (LXRX) had Goodwill of $44.54 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:Goodwill · last filed 2026-08-06
- 2026-06-30: Goodwill $44.54M.
- 2026-03-31: Goodwill $44.54M.
- 2025-12-31: Goodwill $44.54M.
- 2025-09-30: Goodwill $44.54M.
| Period end | Goodwill |
|---|---|
| 2026-06-30 | $44.54M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $44.54M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $44.54M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $44.54M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $44.54M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $44.54M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $44.54M 10-K · filed 2026-03-05 |
| 2024-09-30 | $44.54M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $44.54M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $44.54M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $44.54M 10-K · filed 2025-03-07 |
| 2023-09-30 | $44.54M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $44.54M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $44.54M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $44.54M 10-K · filed 2024-03-25 |
| 2022-09-30 | $44.54M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $44.54M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $44.54M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $44.54M 10-K · filed 2023-03-03 |
| 2021-09-30 | $44.54M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $44.54M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $44.54M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $44.54M 10-K · filed 2022-03-10 |
| 2020-09-30 | $44.54M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $44.54M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $44.54M 10-Q · filed 2020-04-27 |
| 2019-12-31 | $44.54M 10-K · filed 2021-03-12 |
| 2019-09-30 | $44.54M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $44.54M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $44.54M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $44.54M 10-K · filed 2020-03-12 |
| 2018-09-30 | $44.54M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $44.54M 10-Q · filed 2018-07-30 |
| 2018-03-31 | $44.54M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $44.54M 10-K · filed 2019-03-15 |
| 2017-09-30 | $44.54M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $44.54M 10-Q · filed 2017-08-01 |
| 2017-03-31 | $44.54M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $44.54M 10-K · filed 2018-03-01 |
| 2016-09-30 | $44.54M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $44.54M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $44.54M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $44.54M 10-K · filed 2017-03-06 |
| 2015-09-30 | $44.54M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $44.54M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $44.54M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $44.54M 10-K · filed 2016-03-11 |
| 2014-09-30 | $44.54M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $44.54M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $44.54M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $44.54M 10-K · filed 2015-03-12 |
| 2013-09-30 | $44.54M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $44.54M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $44.54M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $44.54M 10-K · filed 2014-03-07 |
| 2012-09-30 | $44.54M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $44.54M 10-Q · filed 2012-08-02 |
| 2012-03-31 | $44.54M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $44.54M 10-K · filed 2013-03-11 |
| 2011-09-30 | $44.54M 10-Q · filed 2011-11-01 |
| 2011-06-30 | $44.54M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $44.54M 10-K · filed 2012-03-08 |
| 2010-07-30 | $44.50M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |